Vericel(VCEL)

View 11 open jobs Website LinkedIn Careers Page

Focus: Vericel is a public biotechnology company headquartered in Burlington, MA specializing in cellular therapy across multiple therapeutic indications including critical limb ischemia, osteonecrosis, and cartilage defects. The company maintains a focused pipeline of autologous cell therapies with advanced clinical programs in Phase 2–3 development.

Cell Therapy

Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

1-50

Total Funding

$6.5M

Open Jobs

11-9 this month

Cooling — net -9 jobs in 30d

9 added, 18 removed. Slower than typical.

Should You Work at Vericel?

AI assessment

Best suited for manufacturing, quality, and commercial-track professionals seeking exposure to cell therapy and public-company execution with acceptable downside risk; less ideal for research-focused scientists or those seeking large team environments.

Why Work Here

Revenue-generating public company ($198M in FY 2025) with improving financial trajectory, providing career stability rare in early-stage biotech.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$198M

Pipeline & Clinical Trials

Carticel

Articular Cartilage

N/A

Clinical Trials (1)

NCT00140634The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

N/A

Help build intelligence for Vericel

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Manufacturing-heavy hiring (6 of 20 active roles) signals scaling of production capabilities for commercialization of multiple Phase 3 programs.

Focused pipeline of 15 active programs spanning three modalities (ixmyelocel-T, autologous chondrocytes, tissue repair cells) de-risks single-program dependency.

Watch Out For

Very small headcount (1–50 employees) limits internal advancement opportunities and creates flat organizational structure with fewer mentorship pathways.
Recent insider stock sales and analyst undervaluation signals raise questions about investor confidence and near-term stock performance.
Low R&D intensity (11%) and modest R&D spend ($21M) suggest limited research infrastructure compared to peers, potentially constraining scientific careers.

Generated by Claude from Vericel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

autologous cultured chondrocytes on porcine collagen membrane

Articular Cartilage Defects

N/A

Clinical Trials (1)

NCT01251588Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

N/A

Fracture surgery

Fracture, Ununited

PHASE_1_2

Clinical Trials (1)

NCT00424567Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

Phase 1/2

Tissue Repair Cells

Alveolar Bone Loss

PHASE_1_2

Clinical Trials (1)

NCT00755911Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Phase 1/2

Bone Repair Cells

Single Level Posterolateral Spinal Fusion

PHASE_1_2

Clinical Trials (1)

NCT00797550Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

Phase 1/2

ixmyelocel-T

Ischemic Dilated Cardiomyopathy (IDCM)

PHASE_2

Clinical Trials (1)

NCT01670981An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Phase 2

Ixmyelocel-T

Dilated Cardiomyopathy

PHASE_2

Clinical Trials (1)

NCT00765518Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Phase 2

Ixmyelocel-T

Dilated Cardiomyopathy

PHASE_2

Clinical Trials (1)

NCT01020968Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Phase 2

Ixmyelocel-T

Peripheral Arterial Disease

PHASE_2

Clinical Trials (1)

NCT00468000Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Phase 2

Ixmyelocel-T

Osteonecrosis

PHASE_3

Clinical Trials (1)

NCT00505219Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Phase 3

autologous cultured chondrocytes on porcine collagen membrane

Articular Cartilage Defect

PHASE_3

Clinical Trials (1)

NCT00719576Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

Phase 3

autologous cultured chondrocytes on porcine collagen membrane

Chondral Defect

PHASE_3

Clinical Trials (1)

NCT06915233A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

Phase 3

Ixmyelocel-T

Critical Limb Ischemia

PHASE_3

Clinical Trials (1)

NCT01483898An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Phase 3

MACI

Chondral Defect

PHASE_3

Clinical Trials (1)

NCT03588975A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Phase 3

Carticel

Articular Cartilage

PHASE_4

Clinical Trials (1)

NCT00158613Study of the Treatment of Articular Repair (STAR)

Phase 4

Interview Prep Quick Facts

Founded: 2024

Portfolio: 15 clinical trials

Top TAs: Cardiovascular

Publications: 22 in PubMed

SEC Filings: 2 available

Open Roles: 11 active jobs

Therapeutic Area Focus

Cardiovascular

3 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$198M20%

R&D Spend

$21M(11%)6%

Net Income

-$3M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Upskilling the cell therapy manufacturing workforce: design, implementation, and evaluation of a massive open online course.

Advances in physiology education

2024

PMID:38813607

Establishing Consensus of Best Practice for CEA Use in Treatment of Severe Burns: A US Burn Provider Delphi Study.

Journal of burn care & research : official publication of the American Burn Association

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Vericel(VCEL)

Should You Work at Vericel?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Vericel(10)

Open Jobs (11)

Materials Associate, II

Senior Financial Analyst

Sr. Manager, Promotional Planning & Marketing Operations

Account Manager, Burn Care

Director, Human Resources

Director, Facilities & Engineering

Quality Assurance Specialist, I

CRM Systems Manager, IT

Product Marketing Manager

Quality Control Analyst, II

Financials (FY2025)

Hiring Trend

Research Publications(10)